All News

Based on results from the phase 3 TROPiCS trial, the FDA has granted priority review to sacituzumab govitecan-hziy for unresectable locally advanced or metastatic hormone receptor–positive, HER2-negative breast cancer.

Jun J. Mao, MD, MSCE, spoke about updated guidelines from ASCO and SIO for pain management in patients with cancer.

Data from the phase 3 SUNLIGHT study highlighted the increased survival benefit of trifluridine/tipiracil plus bevacizumab compared with trifluridine/tipiracil alone for the treatment of metastatic colorectal cancer.

Co-editor-in-Chief Howard S. Hochster, MD, highlights exciting clinical trials that may set future standards for adjuvant therapy selection in colon cancer.

Kevin Kalinsky, MD, MS, spoke about future studies following results from the phase 2 MAINTAIN trial of ribociclib with or without endocrine therapy and after progression on a CDK4/6 inhibitor for patients with unresectable or metastatic hormone receptor–positive, HER2-negative breast cancer.

Patients with mantle cell lymphoma experienced higher relative risks of respiratory, blood, and infectious disease relative to the general population, regardless of treatment type.

After review by an independent data monitoring committee, the phase 2 ENVASARC trial, analyzing envafolimab monotherapy or in combination with ipilimumab for patients with undifferentiated pleomorphic sarcoma and myxofibrosarcoma, will proceed as planned.

Patients with metastatic colorectal cancer who were below a certain income level appear to be more susceptible to major financial hardship.

Joseph Mikhael, MD, spoke about the mechanism of action of bispecific antibody teclistamab relative to other agents in the space such monoclonal antibodies and CAR T-cell therapies in multiple myeloma.

Tafasitamab plus lenalidomide prolonged overall survival compared with systemic therapies in patients with relapsed/refractory diffuse large B-cell lymphoma, according to data from the retrospective RE-MIND2 study.

At 2022 IGCS, Lilian Gien, MD, spoke about a phase 2 trial which analyzed pembrolizumab plus epacadostat in patients with recurrent clear cell carcinoma of the ovary.

Following the 2022 American Society of Clinical Oncology Annual Meeting, experts in multiple myeloma discuss real-world evidence as it relates to the present-day treatment of patients.

The PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody was approved by the FDA as a companion diagnostic to help identify patients with HER2-low metastatic breast cancer who may be eligible to receive fam-trastuzumab deruxtecan-nxki.

The MAINTAIN trial was designed to assess endocrine therapy with or without ribociclib after progression on a CDK4/6 inhibitor in patients with unresectable or metastatic hormone receptor–positive, HER2-negative breast cancer.

Minimal residual disease negativity might be an important prognostic indicator in patients with newly diagnosed multiple myeloma, investigators say.

Findings of the phase 2 PERLA trial indicated that dostarlimab combined with chemotherapy achieved promising responses in patients with metastatic non-squamous non-small cell lung cancer.

Receipt of red blood cell transfusions can negatively impact survival outcomes in patients with endometrial cancers, while ovarian cancers were most affected by preoperative global health status.

Patients with locally advanced or metastatic EGFR-mutant nonsquamous non–small cell lung cancer who progressed on an EGFR inhibitor may benefit from treatment with sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy vs chemotherapy alone.

Data from a pivotal phase 3 trial support a recent biologics license application for denileukin diftitox that was submitted to the FDA.

CancerNetwork spoke with AmerisourceBergen's Lisa Harrison, RPh, about how the new Enhancing Oncology Model and medically integrated dispensing factor into combating health disparities.

Tiffany Sia, MD, spoke about major takeaways from her study and how to implement procedural interventions for patients with gynecologic malignancies who have oligoprogression.

Patients with locally advanced/metastatic non–clear cell renal cell carcinoma experienced promising preliminary antitumor activity following treatment with pembrolizumab and lenvatinib in the first line.

The phase 3 TALAPRO-2 study met the primary end point of radiographic progression-free survival in patients with metastatic castration-resistant prostate cancer with or without homologous recombination repair gene mutations following treatment with a combination of talazoparib and enzalutamide.

A secondary end point analysis of the phase 2 TUXEDO-1 trial found that trastuzumab deruxtecan improved outcomes without significantly impacting quality of life for patients with HER2-positive breast cancer with CNS metastases.

Investigators believe that disease modifying agents may demonstrate benefit in patients with myeloproliferative neoplasms prior to allogeneic hematopoietic cell transplant.

CUE-101 alone or in combination with pembrolizumab was granted fast track designation by the FDA for patients with human papillomavirus 16–positive recurrent/metastatic head and neck squamous cell carcinoma.

Fast track designation was granted to sapanisertib by the FDA for patients with unresectable or metastatic squamous cell non–small cell lung cancer who have an NRF2 mutation.

A recent study presented at IGCS 2022 looking at clinical trial enrollment found that Black patients experienced the biggest increase in accrual following an NCI call-to-action for more diversity in clinical trials.

Results from a phase 2 trial indicated that atezolizumab and bevacizumab yielded a significant duration of response in recurrent endometrial cancer.

Despite inconclusive efficacy results regarding the use of pembrolizumab plus epacadostat in patients with recurrent clear cell ovarian carcinoma, rapid accrual to the trial reveals an unmet need in this cancer subset.